Breaking News

Kiniksa Pharmaceuticals to Report Fourth Quarter and

Kiniksa Pharmaceuticals to Report Fourth Quarter and

HAMILTON, Bermuda, Feb. 18, 2022 (Globe NEWSWIRE) — Kiniksa Prescribed drugs, Ltd. (Nasdaq: KNSA) announced right now that it will host a convention get in touch with and dwell webcast on Tuesday, February 22, 2022, at 8:30 a.m. Eastern Time to report its fourth quarter and full-yr 2021 economical success and company update.

A reside webcast will be accessible by the Buyers & Media segment of the company’s web page at www.kiniksa.com. A replay of the webcast will also be accessible on Kiniksa’s web site in just around 48 several hours of the occasion. The meeting connect with can be accessed by dialing (866) 614-0636 (U.S. and Canada) or (409) 231-2053 (worldwide) employing convention ID quantity 8145539.

About Kiniksa
Kiniksa is a biopharmaceutical company centered on finding, getting, creating, and commercializing therapeutic medicines for sufferers suffering from debilitating diseases with sizeable unmet clinical need. Kiniksa’s portfolio property, ARCALYST®, mavrilimumab, vixarelimab and KPL-404, are based on powerful biologic rationale or validated mechanisms, target underserved problems, and offer you the probable for differentiation. These assets are created to modulate immunological pathways throughout a spectrum of diseases. For a lot more facts, please visit www.kiniksa.com.

ARCALYST® is a registered trademark of Regeneron Prescription drugs, Inc.

Each individual Next Counts! ®

Kiniksa Trader and Media Speak to
Rachel Frank
(339) 970-9437
[email protected]